A new approach to antidepressants and anxiolytics: the microbiota-gut-brain axis
Our understanding of anxiety and depression has evolved over the years, leading to advancements in diagnosis, treatment, and clinical management. However, their prevalence has not lessened; in fact, it has heightened in recent years due to the COVID-19 pandemic. Its effects will last for years to come, so all mechanisms that can influence its incidence should be thoroughly considered, and the gut microbiota is the newest emerging target for antidepressant …